Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

被引:228
作者
Crandall, Jill P. [1 ,2 ,3 ]
Oram, Valerie [1 ]
Rescu, Georgeta Trandafi [1 ,2 ]
Reid, Migdalia [1 ]
Kishore, Preeti [1 ,2 ,3 ]
Hawkins, Meredith [1 ,2 ,3 ]
Cohen, Hillel W. [4 ]
Barzilai, Nir [1 ,2 ,3 ]
机构
[1] Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Diabet Res & Training Ctr, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Inst Aging Res, Bronx, NY 10467 USA
[4] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
来源
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES | 2012年 / 67卷 / 12期
基金
美国国家卫生研究院;
关键词
INSULIN SENSITIVITY; PLATELET-AGGREGATION; RED WINE; IN-VIVO; HYPERGLYCEMIA; BIOAVAILABILITY; MECHANISMS; ACTIVATORS; SECRETION; INDEXES;
D O I
10.1093/gerona/glr235
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Background. Resveratrol, a plant-derived polyphenol, has shown promising effects on insulin sensitivity and glucose tolerance in animal models and is also reported to have cardioprotective properties, but human studies are limited. In a pilot study, we tested the hypothesis that resveratrol improves glucose metabolism and vascular function in older adults with impaired glucose tolerance (IGT). Methods. Ten subjects aged 72 +/- 3 years (M +/- SD) with IGT were enrolled in a 4-week open-label study of resveratrol (daily dose 1, 1.5, or 2 g). Following a standard mixed meal (110 g carbohydrate, 20 g protein, 20 g fat), we measured 3-hour glucose and insulin area under the curve (AUC), insulin sensitivity (Matsuda index), and secretion (corrected insulin response at 30 minutes). Endothelial function was assessed by reactive hyperemia peripheral arterial tonometry (reactive hyperemia index) before and 90 minutes postmeal. Results did not differ by dose, so data were combined for analysis. Results. At baseline, body mass index was 29 +/- 5 kg/m(2), fasting plasma glucose 110 +/- 13 mg/dL, and 2-hour glucose 183 +/- 33 mg/dL. After 4 weeks of resveratrol, fasting plasma glucose was unchanged, but peak postmeal (185 +/- 10 vs 166 +/- 9 mg/dL, p = .003) and 3-hour glucose AUC (469 +/- 23 vs 428 +/- 19, p = .001) declined. Matsuda index improved (3.1 +/- 0.5 vs 3.8 +/- 0.5, p = .03), and corrected insulin response at 30 minutes was unchanged (0.6 +/- 0.1 vs 0.5 +/- 0.5, p = .49). There was a trend toward improved postmeal reactive hyperemia index (baseline vs resveratrol postmeal delta -0.4 +/- 0.2 vs 0.2 +/- 0.3, p = .06). Weight, blood pressure, and lipids were unchanged. Conclusions. At doses between 1 and 2 g/day, resveratrol improves insulin sensitivity and postmeal plasma glucose in subjects with IGT. These preliminary findings support the conduct of larger studies to further investigate the effects of resveratrol on metabolism and vascular function.
引用
收藏
页码:1307 / 1312
页数:6
相关论文
共 38 条
[1]
Evaluation of insulin sensitivity and glucose effectiveness during a standardized breakfast test: comparison with the minimal model analysis of an intravenous glucose tolerance test [J].
Aloulou, K ;
Brun, JF ;
Mercier, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (05) :676-690
[2]
A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in Mice [J].
Barger, Jamie L. ;
Kayo, Tsuyoshi ;
Vann, James M. ;
Arias, Edward B. ;
Wang, Jelai ;
Hacker, Timothy A. ;
Wang, Ying ;
Raederstorff, Daniel ;
Morrow, Jason D. ;
Leeuwenburgh, Christiaan ;
Allison, David B. ;
Saupe, Kurt W. ;
Cartee, Gregory D. ;
Weindruch, Richard ;
Prolla, Tomas A. .
PLOS ONE, 2008, 3 (06)
[3]
Mechanisms of the age-associated deterioration in glucose tolerance - Contribution of alterations in insulin secretion, action, and clearance [J].
Basu, R ;
Breda, E ;
Oberg, AL ;
Powell, CC ;
Dalla Man, C ;
Basu, A ;
Vittone, JL ;
Klee, GG ;
Arora, P ;
Jensen, MD ;
Toffolo, G ;
Cobelli, C ;
Rizza, RA .
DIABETES, 2003, 52 (07) :1738-1748
[4]
Resveratrol improves health and survival of mice on a high-calorie diet [J].
Baur, Joseph A. ;
Pearson, Kevin J. ;
Price, Nathan L. ;
Jamieson, Hamish A. ;
Lerin, Carles ;
Kalra, Avash ;
Prabhu, Vinayakumar V. ;
Allard, Joanne S. ;
Lopez-Lluch, Guillermo ;
Lewis, Kaitlyn ;
Pistell, Paul J. ;
Poosala, Suresh ;
Becker, Kevin G. ;
Boss, Olivier ;
Gwinn, Dana ;
Wang, Mingyi ;
Ramaswamy, Sharan ;
Fishbein, Kenneth W. ;
Spencer, Richard G. ;
Lakatta, Edward G. ;
Le Couteur, David ;
Shaw, Reuben J. ;
Navas, Placido ;
Puigserver, Pere ;
Ingram, Donald K. ;
de Cabo, Rafael ;
Sinclair, David A. .
NATURE, 2006, 444 (7117) :337-342
[5]
Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[6]
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia [J].
Bonetti, PO ;
Pumper, GM ;
Higano, ST ;
Holmes, DR ;
Kuvin, JT ;
Lerman, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2137-2141
[7]
Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[8]
Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis [J].
Brown, Victoria A. ;
Patel, Ketan R. ;
Viskaduraki, Maria ;
Crowell, James A. ;
Perloff, Marjorie ;
Booth, Tristan D. ;
Vasilinin, Grygoriy ;
Sen, Ananda ;
Schinas, Anna Maria ;
Piccirilli, Gianfranca ;
Brown, Karen ;
Steward, William P. ;
Gescher, Andreas J. ;
Brenner, Dean E. .
CANCER RESEARCH, 2010, 70 (22) :9003-9011
[9]
Brun JF, 2010, ACTA DIABETOL
[10]
Resveratrol is a selective human cytochrome P450 1A1 inhibitor [J].
Chun, YJ ;
Kim, MY ;
Guengerich, FP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :20-24